p53 protein expression in HER2-negative breast invasive ductal carcinoma.
10.11817/j.issn.1672-7347.2014.10.005
- Author:
Zhenzhen QING
1
;
Wen ZOU
;
Jiadi LUO
;
Qiuyuan WEN
;
Songqing FAN
Author Information
1. Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Journal Article
- MeSH:
Breast Neoplasms;
genetics;
metabolism;
Carcinoma, Ductal;
genetics;
metabolism;
Female;
Humans;
Immunohistochemistry;
Kaplan-Meier Estimate;
Lymphatic Metastasis;
Prognosis;
Receptor, ErbB-2;
Tumor Suppressor Protein p53;
genetics;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2014;39(10):1016-1022
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the expression of p53 and its clinical significance in HER2-negative breast invasive ductal carcinoma (BIDC).
METHODS:The expression of p53, ER and PR in the HER2-negative BIDC was detected by immunohistochemistry and the results were analyzed by SPSS10.0 software packet, chi-square test, spearman's correlation analysis, Kaplan-Meier survival curves and Cox regression analysis.
RESULTS:The positive expression of p53 protein in BIDC with pathological grade III was significantly higher than that with grade I (P<0.05), but there was no significant correlation between the expression of p53 and age, clinical stage, or lymph node metastasis status in the BIDC. The positive expression of p53 protein in BIDC with ER-positive was significantly lower than that with ER-negative (P<0.01). The positive expression of p53 protein was significantly lower in BIDC with common expression of ER and PR than that with negative expression of ER or PR (P<0.05). The HER2-negative BIDC patients with p53-positive expression had a lower 5 year survival than those with p53-negative expression.
CONCLUSION:The positive expression of p53 protein might have significant prognostic value and is an independent prognostic marker in HER2 -negative BIDC.
